Multispecific Antibody pH-Sensitive Binding for Brain Uptake

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current monoclonal antibodies with high affinity for the blood-brain barrier (BBB) receptors face limitations in brain penetration due to rapid saturation, leading to restricted uptake and distribution in the central nervous system (CNS), and may cause adverse effects such as reticulocyte depletion.

Innovation Solution

Development of multispecific antibodies with lower affinity for BBB receptors, specifically designed to bind to transferrin receptor (TfR) and BACE1, which are engineered to reduce effector function and complement activation, and pH-sensitive binding to minimize side effects and enhance CNS delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If high-affinity antibodies are used to target BBB receptors, then receptor binding is improved, but brain penetration and CNS distribution are limited due to rapid saturation

Engineering Contradiction:

Improvereceptor binding affinityVSAvoidbrain uptake and CNS distribution

Core Design Contradiction:

StrengthVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by engineering antibodies with modified binding affinity to TfR. Specifically, the invention creates variants with reduced affinity (higher KD values) compared to wild-type antibodies, allowing sustained transcytosis without rapid saturation of BBB receptors, thereby improving brain penetration and CNS distribution

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements dynamics by creating pH-sensitive antibodies that exhibit different binding characteristics at different pH levels. The antibodies bind with higher affinity at physiological pH (7.4) for efficient uptake but reduce affinity in endosomal compartments (pH 5.0-6.0), preventing entrapment and enabling release into the brain parenchyma

Inventive Principle:

Principle #15Dynamics

2Productivity

If high-affinity anti-TfR antibodies are administered, then BBB transport is enhanced, but reticulocyte depletion and acute clinical symptoms occur

Engineering Contradiction:

ImproveBBB transport efficiencyVSAvoidreticulocyte depletion and acute clinical symptoms

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent reduces harmful effects by engineering antibodies with lowered affinity for TfR (increased KD values). This reduced affinity decreases the likelihood of saturating TfR on reticulocytes, thereby minimizing reticulocyte depletion and associated acute clinical symptoms while maintaining adequate BBB transport capacity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs pH-sensitive dynamics to reduce off-target effects. The antibodies are engineered to bind TfR with high affinity at physiological pH in the bloodstream but exhibit reduced affinity in the acidic environment of endosomes and on reticulocytes, thereby selectively minimizing reticulocyte depletion while maintaining brain uptake

Inventive Principle:

Principle #15Dynamics

3Object-affected harmful factors

If low-affinity antibodies are used, then reticulocyte depletion is reduced, but BBB transport efficiency may be compromised

Engineering Contradiction:

Improvereticulocyte depletionVSAvoidBBB transport efficiency

Core Design Contradiction:

Object-affected harmful factorsVSProductivity

Solution Approach 1:

The patent resolves this contradiction through pH-sensitive dynamics. The antibodies maintain high binding affinity at physiological pH (7.4) in the bloodstream for efficient TfR-mediated transcytosis, but automatically reduce affinity in acidic endosomal compartments (pH 5.0-6.0), preventing saturation and enabling sustained transport while minimizing reticulocyte depletion

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent applies multi-functionality by engineering antibodies that simultaneously exhibit pH-dependent affinity modulation and reduced overall affinity. This dual characteristic allows the same antibody to function effectively for BBB transport while minimizing harmful effects on reticulocytes

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The lower-affinity antibodies achieve significant brain uptake and distribution of therapeutic molecules, reducing adverse effects and allowing for sustained therapeutic concentrations, thereby improving treatment efficacy and reducing dosing frequency for CNS diseases like Alzheimer's.

Implementation Method 1

Strategies to maximize brain uptake while minimizing reverse transcytosis back to the blood, and to also maximize the extent of accumulation after therapeutic dosing have been addressed with the finding that antibodies with low affinity to BBB receptors offer the potential to substantially increase BBB transport and CNS retention of associated therapeutic moieties/molecules

Methodology Applied

Scientific EffectReceptor-mediated transcytosis: